2025
Performance characteristics and potential public health impact of improved pre-erythrocytic malaria vaccines targeting childhood burden
Malinga J, Braunack-Mayer L, Masserey T, Cavelan A, Chandramohan D, Dicko A, Ouédraogo J, Kelly S, Le Rutte E, Nekkab N, Penny M. Performance characteristics and potential public health impact of improved pre-erythrocytic malaria vaccines targeting childhood burden. PLOS Global Public Health 2025, 5: e0004549. PMID: 40758687, PMCID: PMC12321141, DOI: 10.1371/journal.pgph.0004549.Peer-Reviewed Original ResearchPre-erythrocytic vaccineMalaria vaccineChildhood malariaDuration of protectionIndividual-based model of malaria transmissionPre-erythrocytic malaria vaccineModel of malaria transmissionMalaria vaccine developmentRTS,SSevere childhood malariaRTS,S/AS01Public health impactIncidence reductionRoutine immunization programSeasonal vaccineMalaria transmissionClinical endpointsPotential public health impactVaccine efficacyPrimary vaccinationYear boosterMalariaVaccine developmentVaccine propertiesTrial data
2020
The duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data
Bretscher M, Dahal P, Griffin J, Stepniewska K, Bassat Q, Baudin E, D’Alessandro U, Djimde A, Dorsey G, Espié E, Fofana B, González R, Juma E, Karema C, Lasry E, Lell B, Lima N, Menéndez C, Mombo-Ngoma G, Moreira C, Nikiema F, Ouédraogo J, Staedke S, Tinto H, Valea I, Yeka A, Ghani A, Guerin P, Okell L. The duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data. BMC Medicine 2020, 18: 47. PMID: 32098634, PMCID: PMC7043031, DOI: 10.1186/s12916-020-1494-3.Peer-Reviewed Original ResearchConceptsFirst-line treatmentDuration of chemoprophylaxisPost-treatment prophylaxisIndividual patient dataAS-AQArtemether-lumefantrinePlasmodium falciparum malaria casesPfcrt 76TPatient dataFalciparum malaria casesPotential public health impactHigh transmission areasDuration of protectionLonger protectionPublic health impactTransmission intensityWild-type Pfmdr1Pfmdr1 86YMalaria morbidityClinical incidenceMean durationClinical trialsChemoprevention programMultivariable modelHigh prevalence
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply